Entry into a Material Definitive Agreement. On September 4, 2026, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Agreement”) with Foldlab AI Ltd., a company organized under the laws of British Columbia (“Foldlab” or the “Seller”), pursuant to which the Company will acquire from Foldlab certain artificial intelligence software, models, source code, data rights, intellectual property and related assets (collectively, the “Transferred Asset…

CEO — Katharyn Field: The CEO transitioned out of the role to an advisory capacity with an immediate external successor appointed, indicating an orderly succession rather than a sudden loss of leadership.

Entry into a Material Definitive Agreement. On August 12, 2026, iSpecimen Inc. (the “Company”) entered into a Consulting Agreement (the “Consulting Agreement”) with IR Agency LLC (the “Consultant”), pursuant to which the Consultant agreed to provide marketing and advertising services designed to communicate information about the Company to the financial community, including the creation of company profiles and media distribution. The Consulting Agreement provides for a three-month term commen…

Termination of a Material Definitive Agreement. As described in

Entry into a Material Definitive Agreement. On August 6, 2026, iSpecimen Inc. (the “Company”) entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with WestPark Capital, Inc. (“WestPark”) to resolve all disputes between them, including the arbitration captioned WestPark Capital, Inc. v. iSpecimen, Inc. , JAMS Ref. No. 5425005724 (the “Arbitration”). The Arbitration arose from engagement agreements dated on or about July 31, 2025 and October 15, 2025 (together, t…

Entry into a Material Definitive Agreement. On August 5, 2026, iSpecimen Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with E.F. Hutton & Co. (the “Placement Agent”), and a securities purchase agreement (the “Purchase Agreement”) with investors in connection with which the Company agreed to issue and sell, in a “reasonable best efforts” public offering (the “Offering”) (i) 996,231 shares (the “Shares”) of the Company’s common stock, par valu…

Other Events. On July 9, 2026, iSpecimen Inc. (the “Company”) completed Milestone 3 in the Company’s digital transformation program powered by SalesStack Solutions. Pursuant to Section 3.1 of the Definitive Software Purchase and Services Agreement between the Company and Sales Stack Solutions Corp. (the “SalesStack Agreement”), filed as Exhibit 10.46 to the Company’s Registration Statement on Form S-1/A filed on June 11, 2025, the Company made a payment of $700,000 upon completion of Mileston…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 29, 2026, iSpecimen Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Mar…

Unregistered Sales of Equity Securities. The issuance and sale of the Shares and Pre-Funded Warrants at the Closing were made, and the issuance of the Warrant Shares upon exercise of the Pre-Funded Warrants will be made, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering. The Investors r…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2025, on November 19, 2025, the Company received a written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.…

Entry into a Material Definitive Agreement. On May 8, 2026, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell 488,281 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock” or “Shares”), at a purchase price of $5.12 per Share. In lieu of Shares that would otherwise…

Director — Ms. Siyun Yang: Ms. Siyun Yang resigned as a director of iSpecimen Inc.

Regulation FD Disclosure. On February 6, 2026, iSpecimen Inc. (the “Company”) issued two press releases. The first press release announced the successful completion of Milestone 2 in the Company’s digital transformation program powered by SalesStack Solutions and the activation of the Company’s live production marketplace. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The second press release highlights recent operational achievements demonstrat…

Entry into a Material Definitive Agreement. As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 2, 2026, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), completed a private placement, on December 31, 2025, of its Series C Convertible Non-Voting Preferred Stock. On December 31, 2025, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with IR Agency LLC (the “Consultant”…

Unregistered Sales of Equity Securities. The issuance and sale of the Series C Preferred Stock at the Closing was made, and the issuance and sale of the additional Conversion Shares will be made, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering. The Investors represented that they are…

Entry into a Material Definitive Agreement. On December 30, 2025, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to sell, and the Investors agreed to purchase, 6,875 shares of the Company’s newly-designated Series C Convertible Non-Voting Preferred Stock, par value $0.0001 per share (the “Series C Preferred St…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2025, iSpecimen Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing…

Chief Executive Officer, President, Secretary, and Treasurer — Katharyn Field: Ms. Katharyn Field was promoted to Chief Executive Officer, President, Secretary, and Treasurer.

Regulation FD Disclosure. On August 21, 2025, iSpecimen Inc. (the “Company”) issued a press release announcing the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This achievement marks the installation of the new Salestack platform and provisioning of modern infrastructure. The Company is now positioned to advance to Milestone 2 (Integration), which will focus on connecting all parts of the Company’s business to the Salestack platfor…

Regulation FD Disclosure. On July 31, 2025, the Company issued a press release announcing the pricing of the Private Placement described in

Entry into a Material Definitive Agreement. On July 31, 2025, iSpecimen Inc. (Nasdaq: ISPC) (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company issued and sold, in a private placement (the “Private Placement”), an aggregate of 1,559,828 shares of its common stock, par value $0.0001 per share (the “Common Stock”), or, in lieu thereof, pre-funded warrants to purchase shares of…

Director — Richard J. Paolone, John L. Brooks III: Two directors resigned from the Board without any disagreement with the Company.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 4, 2025, iSpecimen Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. As reported in the Company’s Quarterly Rep…

Changes in Registrant’s Certifying Accountant. On March 7, 2025, iSpecimen Inc. (the “Company”) was notified that Wolf & Company, P.C. (“Wolf & Company”) resigned as the Company’s independent registered public accounting firm, effective immediately. Wolf & Company’s audit reports for the fiscal years ended December 31, 2023, and December 31, 2022, did not contain an adverse opinion, or a disclaimer nor was it qualified or modified as to uncertainty, audit scope, or accounting principles. Howe…

Katharyn Field: Ms. Katharyn Field's employment terms and compensation were disclosed.